---
id: nccn-bladder-2025
title: "NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer"
short_title: "Bladder Cancer"
organization: National Comprehensive Cancer Network
country: United States
url: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417
specialty: oncology
guideline_type: clinical-practice
evidence_system: nccn
conditions:
  - Bladder Cancer
  - Urothelial Carcinoma
  - Muscle-Invasive Bladder Cancer
tags:
  - bladder cancer
  - urothelial cancer
  - cystectomy
  - immunotherapy
  - BCG
publication_date: 2025-01-10
previous_version_date: 2024-01-15
status: current
supersedes: nccn-bladder-2024
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This guideline provides recommendations for the diagnosis, staging, and treatment of bladder cancer, including non-muscle invasive and muscle-invasive disease.

## Key Recommendations

### Diagnosis and Staging
- Cystoscopy with biopsy
- Transurethral resection of bladder tumor (TURBT)
- CT urography for upper tract evaluation
- Chest CT and bone scan for muscle-invasive disease

### Non-Muscle Invasive Bladder Cancer (NMIBC)
**Low-Risk (Ta low-grade, single, <3cm):**
- TURBT + single immediate intravesical chemotherapy
- Surveillance cystoscopy

**Intermediate-Risk:**
- TURBT + intravesical BCG or chemotherapy (mitomycin, gemcitabine)
- Maintenance BCG for 1 year

**High-Risk (T1, CIS, high-grade):**
- TURBT with restaging at 4-6 weeks
- Intravesical BCG induction + maintenance (3 years)
- Consider cystectomy for BCG-unresponsive disease
- Pembrolizumab for BCG-unresponsive NMIBC (CIS)

### Muscle-Invasive Bladder Cancer (MIBC)
**Neoadjuvant Therapy:**
- Cisplatin-based neoadjuvant chemo (MVAC, ddMVAC, GC)
- Improves survival; administer before cystectomy

**Surgery:**
- Radical cystectomy with pelvic lymph node dissection
- Urinary diversion (ileal conduit or neobladder)

**Adjuvant Therapy:**
- Nivolumab for residual disease post-cystectomy
- Adjuvant chemo if no neoadjuvant given

### Metastatic Disease
**First-Line:**
- Cisplatin-eligible: GC with pembrolizumab or avelumab maintenance
- Cisplatin-ineligible: Pembrolizumab or atezolizumab (if PD-L1+)
- Enfortumab vedotin + pembrolizumab (preferred)

**Second-Line and Beyond:**
- Enfortumab vedotin
- Erdafitinib (FGFR alterations)
- Sacituzumab govitecan
